NEWS MyOme, a leading clinical whole genome testing and polygenic risk modelling (PRS) company, announced the launch of its Type 2 Diabetes (T2D) Integrated Polygenic Risk Score™ (iPRS). The new report, available as part of MyOme’s Proactive Health products, empowers individuals and their healthcare providers with a more comprehensive understanding of inherited risk for developing T2D, one of the most prevalent chronic diseases worldwide. According to the Centers for Disease Control and Prevention (CDC), more than 1 in 10 Americans—over 37 million people—have diabetes, with T2D accounting for 90–95% of cases.¹ An additional 96 million U.S. adults—over 1 in 3—have prediabetes, placing them at increased risk for developing T2D.² Diabetes is the eighth leading cause of death in the United States, contributing to approximately 100,000 deaths annually, MyOme Expands Proactive Health Portfolio with Launch of Type 2 Diabetes Integrated Polygenic Risk Score (iPRS)™ and is recognized as a major public health concern by the CDC, NIH, and American Diabetes Association.³ The T2D iPRS combines insights from ~1.3 million genetic risk factors with clinical inputs from an individual’s health history to deliver a more comprehensive and personalized assessment of T2D risk. By integrating both rare and common variants, MyOme’s iPRS goes beyond traditional genetic testing to provide a fuller picture of risk that can inform earlier interventions and more tailored health decisions. By preventing or postponing disease onset, patients can enjoy longer, healthier lives, while health systems, employers, and insurers may see economic benefits. “Our mission at MyOme is to enable people to take control of their health through their whole genome,” said Dr. Akash Kumar, Chief Medical Officer at MyOme, “The addition of our T2D iPRS to our CAD iPRS strengthens our cardiometabolic portfolio, addressing two interrelated conditions that affect hundreds of millions globally. By combining insights into both cardiovascular and diabetes risk, we equip providers and patients with actionable tools to better guide prevention and long-term health.” The T2D iPRS joins MyOme’s growing portfolio of Proactive Health offerings, which include: • Single-Gene Screen Report: Identifies disease-causing variants in genes linked to a range of conditions including cancers, heart disease, and metabolic and inflammatory disorders. • Medication Response Report: Detects genetic variants that influence how individuals metabolize commonly prescribed medications.
RkJQdWJsaXNoZXIy MTUyMDQwMA==